BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia-Reference-Cited by-全球学者库

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Published:2017-04-27 Issue:29 Volume:8 Page:47103-47109
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Vidal Valérie¹,Robert Guillaume²,Goursaud Laure¹,Durand Laetitia¹,Ginet Clemence²,Karsenti Jean Michel³,Luciano Frederic²,Gastaud Lauris⁴,Garnier Georges⁵,Braun Thorsten⁶,Hirsch Pierre⁷⁸,Raffoux Emmanuel⁹,Nloga Anne Marie¹⁰,Padua Rose Ann¹,Dombret Hervé⁹,Rohrlich Pierre³,Ades Lionel¹¹⁰,Chomienne Christine¹,Auberger Patrick²³,Fenaux Pierre¹¹⁰,Cluzeau Thomas¹²³

Affiliation:

1. INSERM U1131, Institut Universitaire d’hématologie, Paris, France

2. INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Nice, France

3. Cote d'azur University, Nice Sophia Antipolis University, CHU of Nice, Nice, France

4. Centre Antoine Lacassagne, Service d’oncologie, Nice, France

5. CH Princesse Grace, Service de Médecine Interne, Monaco, Monaco

6. Hôpital Avicenne, Paris 13 University, APHP, Bobigny, France

7. Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie Cellulaire, Paris, France

8. Sorbonne Universités, UPMC Univ Paris 6, UMRS 938, CDR Saint-Antoine, Paris, France

9. Hôpital Saint Louis, Paris 7 University, Service d’Hématologie Adulte, APHP, Paris, France

10. Hôpital Saint Louis, Paris 7 University, Service d’Hématologie Sénior, APHP, Paris, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

3. Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors;Best Practice & Research Clinical Haematology;2023-12

4. Bcl-B: an “unknown” protein of the Bcl-2 family;Biology Direct;2023-10-30

5. Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients;HemaSphere;2022-10-25